Esperion Therapeutics Inc. announced the U.S. Food and Drug Administration confirmed that Esperion’s LDL-C lowering program is adequate to support approval of an LDL-C lowering indication for bempedoic acid.
Amgen Inc. said on Monday its injection Repatha significantly reduced the need for patients to undergo a procedure to reduce bad cholesterol, according to the findings of a late-stage study.
Amgen Inc. said its potent cholesterol fighter Repatha significantly reduced the risk of heart attacks, strokes and death in patients with heart disease.
Regeneron CEO Len Schleifer ripped into Amgen for its insistence on blocking sales of a rival cholesterol drug during the appeals process in a patent infringement case.
A federal judge refused to throw out a court verdict upholding two Amgen patents related to its cholesterol drug, a defeat for Sanofi and Regeneron Pharmaceuticals, which make a rival drug.
Sanofi and Regeneron will continue a large clinical outcomes study for the injectable cholesterol-lowering drug Praluent, confounding hopes of an early win.
A new type of heart drug developed by The Medicines Co. significantly lowered “bad” LDL cholesterol in high-risk patients with no major safety issues.
Amgen’s Repatha with statin therapy took “bad” LDL cholesterol down to extremely low levels and caused artery-clogging plaque decline after 18 months’ treatment.
2016 Annual Report: Top 10 Pipelines"Bad" LDL Cholesterol, Alzheimer's Diseases, Approvals, Big Pharma, Biologics License Application (BLA), Biosimilars, Biotech, Biotech/Biopharma, Biotechnology, Bispecific CD19-directed CD3 T cell engager (BiTE) antibodies, Blockbusters, Blood Cancers, Breakthrough Designation, Breakthrough Therapy, Breakthrough Therapy Designation, Breakthrough Therapy Designation, Cells, Chimeric Antigen Receptor T Cell Therapy (CART), Cholesterol, Chronic Lymphocytic Leukemia, Clinical Trials, Collaboration, Collaborations, Collaborations, Cystic Fibrosis, Deals, Diabetes, DNA, EGFR Inhibitors, Europe, European Commission, FDA, FDA/Regulatory, February 2016, Glucagon-Like Peptide-1 (GLP-1) Analogs, Immune Response, Immune System, Immune Systems, Immunotherapies, Influenza, Inhalers, Issue Archives, Mantle Cell Lymphoma (MCL), Monoclonal Antibodies, Multiple Myeloma, NDA, Neuroscience, New Drug Application (NDA), New Molecular Entities, Non-Small Cell Lung Cancer, Oncology, Pain, Parkinson's, Parkinson's Disease, Plaque Psoriasis, Potential Blockbusters, Psoriasis, R&D, Sales, SGLT2 Inhibitors, Special Reports, Specialty Therapy, Technology, TGF-Beta Inhibitors, The New England Journal of Medicine (NEJM), Therapeutics, Top 10 Pipelines, Transforming Growth Factor-beta (TGFb), Type 1 Diabetes, Type 2 Diabetes, Vaccines, Waldenstrom’s macroglobulinemia
The pharma industry’s R&D concentration has been shifting towards specialty therapy areas as research and development returns decline for some leaders.
(Reuters Health) – Eating a handful of walnuts each day might help keep the doctor away, at least for some people who are at risk of developing diabetes, a U.S. […]